RU2012123516A - Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов - Google Patents

Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов Download PDF

Info

Publication number
RU2012123516A
RU2012123516A RU2012123516/15A RU2012123516A RU2012123516A RU 2012123516 A RU2012123516 A RU 2012123516A RU 2012123516/15 A RU2012123516/15 A RU 2012123516/15A RU 2012123516 A RU2012123516 A RU 2012123516A RU 2012123516 A RU2012123516 A RU 2012123516A
Authority
RU
Russia
Prior art keywords
composition
patient
glaucoma
eye
effective amount
Prior art date
Application number
RU2012123516/15A
Other languages
English (en)
Inventor
Эббот Ф. КЛАРК
Вань-Хэн ВАН
Лоретта Грейвз МАКНАТТ
Original Assignee
Алькон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алькон, Инк. filed Critical Алькон, Инк.
Publication of RU2012123516A publication Critical patent/RU2012123516A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Способ лечения глаукомы путем снижения внутриглазного давления, включающий модулирование SAA-индуцированной экспрессии IL-8, и где указанный способ включает введение пациенту, нуждающемуся в этом, терапевтически эффективного количества композиции, содержащей ингибитор p38 MAP киназы.2. Способ по п.1, включающий модулирование SAA-индуцированной экспрессии IL-8 в клетках трабекулярной сети (ТМ) пациентов, страдающих глаукомой.3. Способ по п.1, в котором композицию вводят местно в глаз указанного пациента.4. Способ лечения глазной гипертензии, включающий введение пациенту, нуждающемуся в этом, терапевтически эффективного количества композиции, содержащей ингибитор p38 MAP киназы.5. Способ по п.4, в котором композицию вводят местно в глаз указанного пациента.

Claims (5)

1. Способ лечения глаукомы путем снижения внутриглазного давления, включающий модулирование SAA-индуцированной экспрессии IL-8, и где указанный способ включает введение пациенту, нуждающемуся в этом, терапевтически эффективного количества композиции, содержащей ингибитор p38 MAP киназы.
2. Способ по п.1, включающий модулирование SAA-индуцированной экспрессии IL-8 в клетках трабекулярной сети (ТМ) пациентов, страдающих глаукомой.
3. Способ по п.1, в котором композицию вводят местно в глаз указанного пациента.
4. Способ лечения глазной гипертензии, включающий введение пациенту, нуждающемуся в этом, терапевтически эффективного количества композиции, содержащей ингибитор p38 MAP киназы.
5. Способ по п.4, в котором композицию вводят местно в глаз указанного пациента.
RU2012123516/15A 2006-12-22 2012-06-06 Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов RU2012123516A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/615,454 US7662389B2 (en) 2003-12-17 2006-12-22 Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US11/615,454 2006-12-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009128245/15A Division RU2461378C2 (ru) 2006-12-22 2007-12-17 Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов

Publications (1)

Publication Number Publication Date
RU2012123516A true RU2012123516A (ru) 2013-12-20

Family

ID=39205179

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009128245/15A RU2461378C2 (ru) 2006-12-22 2007-12-17 Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов
RU2012123516/15A RU2012123516A (ru) 2006-12-22 2012-06-06 Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2009128245/15A RU2461378C2 (ru) 2006-12-22 2007-12-17 Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов

Country Status (18)

Country Link
US (2) US7662389B2 (ru)
EP (2) EP2120926A1 (ru)
JP (1) JP2010513563A (ru)
KR (1) KR20090101889A (ru)
CN (1) CN101563081A (ru)
AR (1) AR064499A1 (ru)
AU (1) AU2007337059A1 (ru)
BR (1) BRPI0720847A2 (ru)
CA (1) CA2669916A1 (ru)
CL (1) CL2007003800A1 (ru)
ES (1) ES2424123T3 (ru)
MX (1) MX2009004402A (ru)
RU (2) RU2461378C2 (ru)
SA (1) SA07280713B1 (ru)
TW (1) TW200833842A (ru)
UY (1) UY30837A1 (ru)
WO (1) WO2008079783A1 (ru)
ZA (1) ZA200902454B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
CN101921799B (zh) * 2010-01-18 2014-02-26 德赛诊断系统(上海)有限公司 马血清淀粉样蛋白a1制备方法及表达载体和基因工程菌
WO2011127616A1 (en) * 2010-04-13 2011-10-20 M-Lab Ag Diagnostic methods for glaucoma
CN103160575B (zh) * 2011-12-15 2014-10-01 王荣芳 SAA1β/β纯合子基因型在肝硬化预后诊断及肝硬化诊断中的应用
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
DK2855500T3 (da) * 2012-05-24 2020-09-14 Ionis Pharmaceuticals Inc Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression
WO2015072580A1 (ja) * 2013-11-14 2015-05-21 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
WO2017110093A1 (ja) 2015-12-24 2017-06-29 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
EA201992004A1 (ru) * 2017-04-04 2020-02-20 Кинарус Аг Способы предотвращения или лечения офтальмологических заболеваний
CN112410419A (zh) * 2020-12-17 2021-02-26 德赛诊断系统(上海)有限公司 基于淬灭探针的血清淀粉样蛋白a1基因型的检测方法和试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
WO1994016101A2 (en) 1993-01-07 1994-07-21 Koester Hubert Dna sequencing by mass spectrometry
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
ATE323482T1 (de) * 1999-07-02 2006-05-15 Stuart A Lipton Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途

Also Published As

Publication number Publication date
US7662389B2 (en) 2010-02-16
RU2009128245A (ru) 2011-01-27
US20070208043A1 (en) 2007-09-06
SA07280713B1 (ar) 2012-01-24
WO2008079783A1 (en) 2008-07-03
TW200833842A (en) 2008-08-16
CL2007003800A1 (es) 2008-08-22
MX2009004402A (es) 2009-05-11
AU2007337059A1 (en) 2008-07-03
JP2010513563A (ja) 2010-04-30
EP2428210B1 (en) 2013-07-10
US20100063052A1 (en) 2010-03-11
ZA200902454B (en) 2010-07-28
CA2669916A1 (en) 2008-07-03
KR20090101889A (ko) 2009-09-29
UY30837A1 (es) 2008-07-03
EP2120926A1 (en) 2009-11-25
AR064499A1 (es) 2009-04-08
CN101563081A (zh) 2009-10-21
ES2424123T3 (es) 2013-09-27
RU2461378C2 (ru) 2012-09-20
BRPI0720847A2 (pt) 2014-03-04
EP2428210A1 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
RU2012123516A (ru) Применение гена сывороточного амилоида а для диагностики и лечения глаукомы и идентификации антиглаукомных агентов
RU2009144142A (ru) Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента
RU2017129247A (ru) Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
US20080287915A1 (en) Tissue engineering system with scleral lens
ATE451361T1 (de) Materialien und methoden zur behandlung von koagulationsstörungen
Pescosolido et al. Role of dopaminergic receptors in glaucomatous disease modulation
RU2009144186A (ru) Применение циклоспоринов при лечении пациентов с интраокулярными линзами
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
US20240124538A1 (en) Modulation of Wnt5a to Treat Glaucoma
RU2314102C1 (ru) Способ комплексного лечения дисфункции мейбомиевых желез
EA035966B1 (ru) Применение фармацевтической композиции для местного применения для лечения расстройств лакримальной системы и переднего отрезка глаза
Daneshvar et al. Rho-associated kinase inhibitors: potential future treatments for glaucoma
STONE Use of di-isopropyl fluorophosphate (DFP) in treatment of glaucoma
CN1649575A (zh) 用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法
CN1729981A (zh) 含汉防己甲素的用于防治角膜混浊的眼用药物组合物
Kontkanen et al. Hemorrhagic fever (Puumala virus infection) with ocular involvement
Capella et al. Limbal stem cell deficiency following multiple intravitreal injections
Mesa-Gutierrez et al. Crystalline keratopathy due to kappa chains in a monoclonal gammopathy
SWAN Miotic Therapy of Chronic Glaucoma—Changing Trends
RU2808549C1 (ru) Способ хирургического лечения вертикально-горизонтального косоглазия
US20220133714A1 (en) Extracellular matrix modulating agent
Armstrong Modulation of Inflammation Driven Wound Healing after Glaucoma Surgery
Ueji et al. Case of unilateral pellucid marginal corneal degeneration progressing to corneal perforation with keratoconus in contralateral eye
Richardson Medical control of the glaucomas.